About Synthis Therapeutics
Synthis Therapeutics was founded in 2017 based upon the research of its founder, Dori Thomas-Karyat, an expert in the field of immuno-oncology. Dori has strong connections and partnerships with Washington University where she completed her PhD in Immunology.
Synthis Therapeutics is based in NYC at Alexandria LaunchLabs next to NYU Medical Center. Our academic partnership is with NYU through its research institutes and business incubators. Synthis Therapeutics was a part of the Endless Frontier Labs Accelerator Program 2019-2020 and continues to work with NYU presently.
Synthis Therapeutics is a pre-seed startup with the technology fully owned for its therapeutic platform. Synthis Therapeutics is funded by multiple NCI Phase I SBIR Awards.
Natural regulatory T cells are resistant to calcium release-activated calcium (CRAC/ORAI) channel inhibition
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFa, from CD3 þ CD161 þ T cells to exacerbate gut inflammation